Get started
SAREPTA THERA INCSS

SAREPTA THERA INC

13.921CHFR
−3.064−18.04%
At close at Jun 26, 13:30 GMT
CHF
No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

AB3A chart


Full chart

AB3A upcoming earnings


Next report date
≈
July 30
Report period
Q2 2025
EPS estimate
0.55 CHF
Revenue estimate
‪422.46 M‬ CHF

Key stats


Market capitalization
‪1.11 B‬ CHF
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−2.234 CHF
Net income (FY)
‪213.64 M‬ CHF
Revenue (FY)
‪1.73 B‬ CHF
Shares float
‪93.47 M‬
Beta (1Y)
1.17

Employees


Employees (FY)
‪1.37 K‬
Change (1Y)
+58 +4.41%
Revenue / Employee (1Y)
‪1.26 M‬ CHF
Net income / Employee (1Y)
‪155.72 K‬ CHF

About Sarepta Therapeutics, Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Douglas S. Ingram
Website
sarepta.com
Headquarters
Cambridge
Founded
1980
FIGI
BBG00LVGD035
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Financials


Performance
‪−75%‬
‪−50%‬
‪−25%‬
‪0%‬
‪25%‬
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪‪−700.00 M‬‬
‪‪−350.00 M‬‬
‪0.00‬
‪‪350.00 M‬‬
‪‪700.00 M‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−700.00 M‬‬
‪‪−350.00 M‬‬
‪0.00‬
‪‪350.00 M‬‬
‪‪700.00 M‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪‪−700.00 M‬‬
‪‪−350.00 M‬‬
‪0.00‬
‪‪350.00 M‬‬
‪‪700.00 M‬‬
Debt level and coverage
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪‪−600.00 M‬‬
‪0.00‬
‪‪600.00 M‬‬
‪‪1.20 B‬‬
‪‪1.80 B‬‬
Debt
Free cash flow
Cash & equivalents
Earnings
Next:Jul 30, 2025
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Q2 '25
‪−6.00‬
‪−4.00‬
‪−2.00‬
‪0.00‬
‪2.00‬
Actual
Estimate

AB3A news



No news here

Looks like there's nothing to report right now

Reload

Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

AB3A highest yielding bonds


SRPT5657414
Sarepta Therapeutics, Inc. 1.25% 15-SEP-2027
Yield to maturity
20.66%
Maturity date
Sep 15, 2027

See all AB3A bonds 

Sparks


Curated watchlists where AB3A is featured.

See all sparks 

Frequently Asked Questions


The current price of AB3A is 13.921 CHF — it has decreased by −18.04% in the past 24 hours. Watch SAREPTA THERA INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange SAREPTA THERA INC stocks are traded under the ticker AB3A.
We've gathered analysts' opinions on SAREPTA THERA INC future price: according to them, AB3A price has a max estimate of 148.33 CHF and a min estimate of 7.22 CHF. Watch AB3A chart and read a more detailed SAREPTA THERA INC stock forecast: see what analysts think of SAREPTA THERA INC and suggest that you do with its stocks.
AB3A reached its all-time high on Jun 24, 2024 with the price of 145.362 CHF, and its all-time low was 13.921 CHF and was reached on Jun 26, 2025. View more price dynamics on AB3A chart.
See other stocks reaching their highest and lowest prices.
AB3A stock is 22.01% volatile and has beta coefficient of 1.17. Track SAREPTA THERA INC stock price on the chart and check out the list of the most volatile stocks — is SAREPTA THERA INC there?
Today SAREPTA THERA INC has the market capitalization of ‪1.11 B‬, it has decreased by −16.99% over the last week.
Yes, you can track SAREPTA THERA INC financials in yearly and quarterly reports right on TradingView.
SAREPTA THERA INC is going to release the next earnings report on Jul 30, 2025. Keep track of upcoming events with our Earnings Calendar.
AB3A earnings for the last quarter are −4.07 CHF per share, whereas the estimation was −2.84 CHF resulting in a −43.44% surprise. The estimated earnings for the next quarter are 0.55 CHF per share. See more details about SAREPTA THERA INC earnings.
SAREPTA THERA INC revenue for the last quarter amounts to ‪659.38 M‬ CHF, despite the estimated figure of ‪608.58 M‬ CHF. In the next quarter, revenue is expected to reach ‪422.46 M‬ CHF.
AB3A net income for the last quarter is ‪−396.15 M‬ CHF, while the quarter before that showed ‪144.45 M‬ CHF of net income which accounts for −374.25% change. Track more SAREPTA THERA INC financial stats to get the full picture.
No, AB3A doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jul 21, 2025, the company has ‪1.37 K‬ employees. See our rating of the largest employees — is SAREPTA THERA INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. SAREPTA THERA INC EBITDA is ‪−54.98 M‬ CHF, and current EBITDA margin is 14.30%. See more stats in SAREPTA THERA INC financial statements.
Like other stocks, AB3A shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade SAREPTA THERA INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So SAREPTA THERA INC technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating SAREPTA THERA INC stock shows the strong sell signal. See more of SAREPTA THERA INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.